{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:59Z","timestamp":1784696819435,"version":"3.55.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The advent of conversion therapy for hepatocellular carcinoma (HCC) marks a critical transition from palliative care to curative-intent surgery. While clinical success rates are rising, the molecular determinants of sustained remission remain inadequately defined. We propose that effective downstaging may indicate a comprehensive modulation of the tumor immune microenvironment potentially transitioning it from an immune-excluded to an inflamed phenotype based on early translational correlative data. However, the aggressive therapeutic selective pressure of targeted, immune, and locoregional therapies paradoxically fuels clonal evolution. In specific contexts, this therapeutic stress is hypothesized to drive treatment-resistant subclones through mechanisms such as Wnt\/\u03b2-catenin signaling and metabolic adaptation. To navigate this therapeutic barrier, we advocate shifting the clinical objective from anatomical to biological resectability, operationally defined by a provisional set of measurable criteria including ctDNA clearance, robust CD8+ T-cell infiltration, and tertiary lymphoid structure maturation. By implementing a multidimensional surveillance framework that leverages liquid biopsies and AI-radiomics to track subclonal dynamics and minimal residual disease, clinicians can guide precise surgical interventions and intercept resistance, making a curative horizon attainable.<\/jats:p>","DOI":"10.3389\/fonc.2026.1849485","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:41:02Z","timestamp":1784695262000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From anatomical to biological resectability: navigating adaptive resistance in hepatocellular carcinoma conversion"],"prefix":"10.3389","volume":"16","author":[{"given":"Shitao","family":"Lei","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Hydatid Disease Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Cong","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Hydatid Disease Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Hydatid Disease Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoqiang","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Hydatid Disease Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Hydatid Disease Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Hydatid Disease Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]},{"name":"State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2021","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15052","article-title":"Paradigm shift in the treatment options of hepatocellular carcinoma","volume":"42","author":"Su","year":"2021","journal-title":"Liver Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2461631","article-title":"Advancements in immunotherapy for hepatocellular carcinoma","volume":"25","author":"Ascari","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34652","article-title":"Top advances of the year: Hepatobiliary cancers","volume":"129","author":"Coffman-D'Annibale","year":"2023","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.2800","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2024.01372","article-title":"Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma","volume":"18","author":"Hakoda","year":"2024","journal-title":"Biosci Trends"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418965","article-title":"The current status and future of targeted-immune combination for hepatocellular carcinoma","volume":"15","author":"Hao","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e007366","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232875","article-title":"Interventional oncology meets immuno-oncology: Combination therapies for hepatocellular carcinoma","volume":"313","author":"Bitar","year":"2024","journal-title":"Radiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10762-7","article-title":"HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion","volume":"19","author":"Tang","year":"2025","journal-title":"Hepatol Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573098","article-title":"Lenvatinib versus bevacizumab when combined with PD-1\/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12530-z","article-title":"Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma","volume":"30","author":"Zhu","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9745","DOI":"10.1038\/s41598-024-60379-x","article-title":"Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0479","article-title":"Spatial dynamics of T- and B-cell responses predicts clinical outcome of resectable and unresectable hepatocellular carcinoma","volume":"30","author":"Kurebayashi","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110220","article-title":"Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy","volume":"51","author":"Lin","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4085","article-title":"Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma","volume":"10","author":"Chiang","year":"2024","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-023-01218-y","article-title":"Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence","volume":"15","author":"Zhang","year":"2023","journal-title":"Genome Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-025-02314-w","article-title":"Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response","volume":"24","author":"Zeng","year":"2025","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e013516","DOI":"10.1136\/jitc-2025-013516","article-title":"Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"859-871.e3","DOI":"10.1053\/j.gastro.2024.01.028","article-title":"Transcriptomic-based microenvironment classification reveals precision medicine strategies for pancreatic ductal adenocarcinoma","volume":"166","author":"George","year":"2024","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21873\/anticanres.15454","article-title":"Conversion surgery for hepatocellular carcinoma following molecular therapy","volume":"42","author":"Yamamura","year":"2022","journal-title":"Anticancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1-18","DOI":"10.4251\/wjgo.v15.i1.1","article-title":"Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma","volume":"15","author":"Liang","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.107003","article-title":"The immune-reinforcements of lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment","volume":"275","author":"Jiang","year":"2025","journal-title":"Immunol Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1097\/HEP.0000000000001401","article-title":"Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99-112","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.021","article-title":"Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: Results from a prospective phase 2 trial","volume":"114","author":"Buckstein","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1716565","article-title":"The key role of staging definitions for assessment of downstaging for hepatocellular carcinoma","volume":"41","author":"Yao","year":"2021","journal-title":"Semin Liver Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08088-1","article-title":"Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma","volume":"31","author":"Vicentin","year":"2021","journal-title":"Eur Radiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12876-024-03298-5","article-title":"Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study","volume":"24","author":"Jia","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12885-023-10898-z","article-title":"Radiographic and \u03b1-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001163","article-title":"Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy","volume":"81","author":"Scheiner","year":"2024","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001155","article-title":"Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16194","article-title":"Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities","volume":"115","author":"Wang","year":"2024","journal-title":"Cancer Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.772195","article-title":"Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: An overview","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2025.116712","article-title":"Application of hepatic artery interventional therapies in the conversion treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"252","author":"Zeng","year":"2026","journal-title":"Am J Surg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S588533","article-title":"TACE combined with targeted immunotherapy: A strategy for liver transplantation conversion and survival benefits in patients with BCLC stage B\/C HCC","volume":"13","author":"Zhang","year":"2026","journal-title":"J Hepatocell Carcinoma"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-026-00180-1","article-title":"Cadonilimab plus lenvatinib combined with stereotactic body radiotherapy for conversion therapy in unresectable or potentially resectable hepatocellular carcinoma: A study protocol","volume":"46","author":"Fu","year":"2026","journal-title":"Curr Med Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32348","article-title":"Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack","volume":"77","author":"Fang","year":"2022","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10781-y","article-title":"The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan","volume":"19","author":"Shimose","year":"2025","journal-title":"Hepatol Int"},{"key":"B48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-021-00237-y","article-title":"Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance","volume":"10","author":"Wang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000536376","article-title":"Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery","volume":"13","author":"Zeng","year":"2024","journal-title":"Liver Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.16.562104","article-title":"Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade","volume":"8","author":"Shu","year":"2023","journal-title":"bioRxiv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae075","article-title":"Increased IFN-\u03b2 indicates better survival in hepatocellular carcinoma treated with radiotherapy","volume":"218","author":"Zhang","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.734959","article-title":"Bulk and single-cell profiling of breast tumors identifies TREM-1 as a dominant immune suppressive marker associated with poor outcomes","volume":"11","author":"Pullikuth","year":"2021","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3727\/105221620X15880179864121","article-title":"Immune checkpoint inhibitors in hepatocellular cancer: Current understanding on mechanisms of resistance and biomarkers of response to treatment","volume":"20","author":"Onuma","year":"2020","journal-title":"Gene Expr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1043667","article-title":"Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition","volume":"13","author":"Tao","year":"2023","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"Tran","year":"2022","journal-title":"Hepatology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12036-8","article-title":"Recurrence of hepatocellular carcinoma after complete radiologic response to trans-arterial embolization: A retrospective study on patterns, treatments, and prognoses","volume":"29","author":"Ilagan","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.041","article-title":"Characteristics of liver cancer stem cells and clinical correlations","volume":"379","author":"Cheng","year":"2015","journal-title":"Cancer Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328428","article-title":"Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences","volume":"72","author":"Chen","year":"2023","journal-title":"Gut"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13626-w","article-title":"ASO author refections: Early ctDNA dynamics outperform conventional tumor markers in predicting neoadjuvant therapy response and recurrence in colorectal liver metastases","volume":"30","author":"Wang","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13604-2","article-title":"Early circulating tumor DNA dynamics predict neoadjuvant therapy response and recurrence in colorectal liver metastases: A prospective study","volume":"30","author":"Wang","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e008953","DOI":"10.1136\/jitc-2024-008953","article-title":"Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy","volume":"12","author":"Hua","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002322","article-title":"A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study","volume":"111","author":"Lin","year":"2025","journal-title":"Int J Surg"},{"key":"B66","doi-asserted-by":"publisher","first-page":"oyaf368","DOI":"10.1093\/oncolo\/oyaf368","article-title":"An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma","volume":"31","author":"Pang","year":"2025","journal-title":"Oncologist"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002489","article-title":"Comparing watch-and-wait vs. resection in radiologic complete response after conversion therapy for unresectable hepatocellular carcinoma: correspondence","volume":"86","author":"Luo","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000726","article-title":"Adjuvant and neoadjuvant therapies for hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2023","journal-title":"Hepatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/cancers17020236","article-title":"Next-generation immunotherapy for hepatocellular carcinoma: Mechanisms of resistance and novel treatment approaches","volume":"17","author":"Eghbali","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546886","article-title":"Case report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barr\u00e9 syndrome","volume":"16","author":"Ye","year":"2025","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10104-3","article-title":"Current perspectives on the tumor microenvironment in hepatocellular carcinoma","volume":"14","author":"Santhakumar","year":"2020","journal-title":"Hepatol Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1333864","article-title":"Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1849485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:41:10Z","timestamp":1784695270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1849485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":72,"alternative-id":["10.3389\/fonc.2026.1849485"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1849485","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1849485"}}